Full Press Release Details
Baseline 70% 60% 50% 40% 30% 20% 10% 0% (n=30) (n=27) (n=30) (n=31) * Placebo (n=30) Low doseMedium High dose (n=31) (n=27) dose (n=30) Remission: RMOAS<10, P significant at p< 0.05 2 Primary Endpoint before FDA input * P<0.05 vs. placebo # Retrospective modified overt aggression scale 1 Primary Endpoint based on FDA input 2018 Supernus Pharmaceuticals, Inc.
TPM-IR p<0.01 vs. TPM-IR % Gastrointestinal problem 4% 2% Fatigue % 6.8 Median Monthly Migraine Frequency Pre-vs. Post-Initiation of Trokendi XR Pre-Initiation (n=212) Post-Initiation (n=216) 1 O Neal W et al. Cognitive tolerability and health outcomes with Trokendi XR (extended-release topiramate) in migraineurs. J Pain 2017; 18(4): S67. Retrospective Medical Chart Review TPM-IR = Topiramate immediate release 2018 Supernus Pharmaceuticals, Inc.
Supernus assumes no obligation to update any forward-looking statements except as required by applicable law. Supernus has an Offering Memorandum for the offering to which this communication relates. Before you invest, you should read the Offering Memorandum for more complete information about the issuer and this offering. You may obtain a copy of this Offering Memorandum, including the sections titled Special Note Regarding Forward-Looking Statements and Risk Factors, by calling Jefferies LLC, Equity Syndicate Prospectus Department at (212) 336-7460, JP Morgan Securities LLC at (866) 803-9204 or Cowen & Co., Prospectus Department at (631) 274-2806. 2018 Supernus Pharmaceuticals, Inc.
Further information on these and other factors that could affect these forward-looking statements is contained in Supernus public filings with the Securities and Exchange Commission (SEC) from time to time, including our Annual Report or Form 10-K, which was filed with the Securities and Exchange Commission, and other filings with the SEC. You may get these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov.
The words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", opportunity , "plan", potential , "predict", "project", target , "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. Supernus operations involve risks and uncertainties, many of which are outside its control, and any one of which, or a combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct.